Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH¿AEG¿SEPD¿SEOM¿GETECCU
Mar Riveiro-Barciela; Sabela Carballal; Álvaro Díaz-González; Míriam Mañosa; Javier Gallego-Plazas; Joaquín Cubiella; Paula Jiménez-Fonseca; María Varela; Luis Menchén; Bruno Sangro; Ana Fernández-Montes; Francisco Mesonero; Miguel Ángel Rodríguez-Gandía; Fernando Rivera; María-Carlota Londoño;
Gastroenterol Hepatol. 2024;47:401-32
High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified
Laura Núñez; Francisco Mesonero; Enrique Rodríguez de Santiago; Javier Die; Agustín Albillos; Antonio López-Sanromán;
Gastroenterol Hepatol. 2023;46:369-75
Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy
Edgar Castillo-Regalado; Raquel Ríos; Clàudia Aràjol; Cristina Gely; Lucía Márquez; Margalida Calafat; Carlos González-Muñoza; Fiorella Cañete; Francisco Mesonero; Jordi Guardiola; Esther Garcia-Planella; Míriam Mañosa; Eugeni Domènech;
Gastroenterol Hepatol. 2023;46:164-70